Last reviewed · How we verify
RPN301
RPN301 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.
RPN301 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. Used for Type 2 diabetes mellitus, Obesity or weight management.
At a glance
| Generic name | RPN301 |
|---|---|
| Sponsor | HK inno.N Corporation |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | Phase 3 |
Mechanism of action
RPN301 activates glucagon-like peptide-1 (GLP-1) receptors, which enhance insulin secretion in response to glucose, slow gastric emptying, and promote satiety. The extended half-life formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists, improving patient compliance while maintaining sustained metabolic benefits.
Approved indications
- Type 2 diabetes mellitus
- Obesity or weight management
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
Key clinical trials
- Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Peri Inj. Compared With RPN301 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RPN301 CI brief — competitive landscape report
- RPN301 updates RSS · CI watch RSS
- HK inno.N Corporation portfolio CI